Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride in opioid-induced constipation
NCT01117051Phase 3Terminated
- Sponsor
- Takeda
- Start
- May 2010
- Primary completion
- Aug 2012
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prucalopride in opioid-induced constipation (OIC), sponsored by Takeda. Primary endpoint: Percent of Subjects With an Average Frequency of >=3 Spontaneous Bowel Movements Per Week at 12 weeks. Started May 2010; status: terminated.
02
Drugs
prucalopride
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01117051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117051.